Teplizumab curbs beta-cell death in new-onset type 1 diabetes

02/26/2013 | PhysiciansBriefing.com

Patients with new-onset type 1 diabetes had higher rates of beta-cell death compared with those who had long-standing diabetes and those without diabetes, a study found. However, teplizumab treatment was associated with lower beta-cell death and better beta-cell function in patients with new-onset diabetes, researchers wrote in the journal Diabetes.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations